Page 51 - Read Online

Paridar et al. BCR-ABL and myelodysplastic syndrome

progression. Leukemia 2013;27:1080-9. AM, Lea NC, Mitsopoulos K, Ford K, Nasser E, Seidl T, Mufti GJ.
8. Nacheva EP, Grace CD, Brazma D, Gancheva K, Howard-Reeves Spliceosome mutations exhibit specific associations with epigenetic
J, Rai L, Gale RE, Linch DC, Hills RK, Russell N, Burnett AK, modifiers and proto-oncogenes mutated in myelodysplastic syndrome.
Kottaridis PD. Does BCR/ABL1 positive acute myeloid leukaemia Haematologica 2013;98:1058-66.
exist? Br J Haematol 2013;161:541-50. 24. Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard
9. Neuendorff NR, Schwarz M, Hemmati P, Türkmen S, Bommer C, F, Viguié F, Quesnel B, Beyne-Rauzy O, Solary E, Vey N, Hunault-
Burmeister T, Dörken B, le Coutre P, Arnold R, Westermann J. BCR- Berger M, Fenaux P, Mansat-De Mas V, Delabesse E, Guardiola P,
ABL1(+) acute myeloid leukemia: clonal selection of a BCR-ABL1(-) Lacombe C, Vainchenker W, Preudhomme C, Dreyfus F, Bernard OA,
subclone as a cause of refractory disease with nilotinib treatment. Acta Birnbaum D, Fontenay M; Groupe Francophone des Myélodysplasies.
haematol 2015;133:237-41. TET2 mutation is an independent favorable prognostic factor in
10. Dalla Torre CA, de Martino Lee ML, Yoshimoto M, Lopes LF, Melo myelodysplastic syndromes (MDSs). Blood 2009;114:3285-91.
LN, Caminada de Toledo SR, Duffles Andrade JA. Myelodysplastic 25. Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, Yang J, Wang CZ, Chai
syndrome in childhood: report of two cases with deletion of HY, Qian Z, Xiao GF, Xu WR. Recurrent DNMT3A R882 mutations
chromosome 4 and the Philadelphia chromosome. Leuk Res in Chinese patients with acute myeloid leukemia and myelodysplastic
2002;26:533-8. syndrome. PLoS One 2011;6:e26906.
11. Drummond MW, Lush CJ, Vickers MA, Reid FM, Kaeda J, Holyoake 26. Jin J, Hu C, Yu M, Chen F, Ye L, Yin X, Zhuang Z, Tong H. Prognostic
TL. Imatinib mesylate-induced molecular remission of Philadelphia value of isocitrate dehydrogenase mutations in myelodysplastic
chromosome-positive myelodysplastic syndrome. Leukemia syndromes: a retrospective cohort study and meta-analysis. PloS One
2003;17:463-5. 2014;9:e100206.
12. Haferlach T. Molecular genetics in myelodysplastic syndromes. Leuk 27. Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, Wagner
Res 2012;36:1459-62. K, Chaturvedi A, Sharma A, Wichmann M, Göhring G, Schumann
13. Nybakken GE, Bagg A. The genetic basis and expanding role of C, Bug G, Ottmann O, Hofmann WK, Schlegelberger B, Heuser M,
molecular analysis in the diagnosis, prognosis, and therapeutic design Ganser A. Prognostic significance of ASXL1 mutations in patients
for myelodysplastic syndromes. J Mol Diagn 2014;16:145-58. with myelodysplastic syndromes. J Clin Oncol 2011;29:2499-506.
14. Lee EJ, Podoltsev N, Gore SD, Zeidan AM. The evolving field of 28. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M,
prognostication and risk stratification in MDS: recent developments Tönnissen ER, van der Heijden A, Scheele TN, Vandenberghe P, de
and future directions. Blood rev 2016;30:1-10. Witte T, van der Reijden BA, Jansen JH. Somatic mutations of the
15. Jiang H, Xue Y, Wang Q, Pan J, Wu Y, Zhang J, Bai S, Wang Q, He G, histone methyltransferase gene EZH2 in myelodysplastic syndromes.
Sun A, Wu D, Chen S. The utility of fluorescence in situ hybridization Nat Genet 2010;42:665-7.
analysis in diagnosing myelodysplastic syndromes is limited to cases 29. Kulasekararaj AG, Smith AE, Mian SA, Mohamedali AM,
with karyotype failure. Leuk Res 2012;36:448-52. Krishnamurthy P, Lea NC, Gäken J, Pennaneach C, Ireland R,
16. Yang W, Stotler B, Sevilla DW, Emmons FN, Murty VV, Alobeid B, Czepulkowski B, Pomplun S, Marsh JC, Mufti GJ. TP53 mutations in
Bhagat G. FISH analysis in addition to G-band karyotyping: utility in myelodysplastic syndrome are strongly correlated with aberrations of
evaluation of myelodysplastic syndromes? Leuk Res 2010;34:420-5. chromosome 5, and correlate with adverse prognosis. Br J Haematol
17. Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, 2013;160:660-72.
Hildebrandt B, Kundgen A, Lübbert M, Kunzmann R, Giagounidis 30. Constantinidou M, Chalevelakis G, Economopoulos T, Koffa M,
AA, Aul C, Trümper L, Krieger O, Stauder R, Müller TH, Wimazal F, Liloglou T, Anastassiou C, Yalouris A, Spandidos DA, Raptis S.
Valent P, Fonatsch C, Steidl C. New insights into the prognostic impact Codon 12 ras mutations in patients with myelodysplastic syndrome:
of the karyotype in MDS and correlation with subtypes: evidence from incidence and prognostic value. Ann Hematol 1997;74:11-4.
a core dataset of 2124 patients. Blood 2007;110:4385-95. 31. Haferlach C, Bacher U, Haferlach T, Dicker F, Alpermann T, Kern
18. Bejar R, Steensma DP. Recent developments in myelodysplastic W, Schnittger S. The inv (3)(q21q26)/t(3;3)(q21;q26) is frequently
syndromes. Blood 2014;124:2793-803. accompanied by alterations of the RUNX1, KRAS and NRAS and
19. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, NF1 genes and mediates adverse prognosis both in MDS and in AML:
Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, a study in 39 cases of MDS or AML. Leukemia 2011;25:874-7.
Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch 32. Chen CY, Lin LI, Tang JL, Ko BS, Tsay W, Chou WC, Yao M,
C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski Wu SJ, Tseng MH, Tien HF. RUNX1 gene mutation in primary
J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr myelodysplastic syndrome -- the mutation can be detected early at
WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, diagnosis or acquired during disease progression and is associated
Germing U, Haase D. Revised international prognostic scoring system with poor outcome. Br J Haematol 2007;139:405-14.
for myelodysplastic syndromes. Blood 2012;120:2454-65. 33. Hellström-Lindberg E. Significance of JAK2 and TET2 mutations in
20. Visconte V, Tiu RV, Rogers HJ. Pathogenesis of myelodysplastic myelodysplastic syndromes. Blood Rev 2010;24:83-90.
syndromes: an overview of molecular and non-molecular aspects of 34. Bejar R. Myelodysplastic syndromes diagnosis: what is the role of
the disease. Blood Res 2014;49:216-27. molecular testing? Curr Hematol Malig Rep 2015;10:282-91.
21. Walter MJ, Shen D, Shao J, Ding L, White BS, Kandoth C, Miller CA, 35. Wakayama T, Maniwa Y, Ago H, Kakazu N, Abe T. A variant form of
Niu B, McLellan MD, Dees ND, Fulton R, Elliot K, Heath S, Grillot myelodysplastic syndrome with Ph- minor-BCR/ABL transcript. Int J
M, Westervelt P, Link DC, DiPersio JF, Mardis E, Ley TJ, Wilson Hematol 2001;74:58-63.
RK, Graubert TA. Clonal diversity of recurrently mutated genes in 36. Avgerinou C, Alamanos Y, Zikos P, Lampropoulou P, Melachrinou
myelodysplastic syndromes. Leukemia 2013;27:1275-82. M, Labropoulou V, Tavernarakis I, Aktypi A, Kaiafas P, Raptis
22. Kang MG, Kim HR, Seo BY, Lee JH, Choi SY, Kim SH, Shin JH, C, Kouraklis A, Karakantza M, Symeonidis A. The incidence of
Suh SP, Ahn JS, Shin MG. The prognostic impact of mutations in myelodysplastic syndromes in Western Greece is increasing. Ann
spliceosomal genes for myelodysplastic syndrome patients without Hematol 2013;92:877-87.
ring sideroblasts. BMC Cancer 2015;15:484. 37. Lesesve JF, Troussard X, Bastard C, Hurst JP, Nouet D, Callat MP,
23. Mian SA, Smith AE, Kulasekararaj AG, Kizilors A, Mohamedali Lenormand B, Piguet H, Flandrin G, Macintyre E. p190bcr/abl
Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ February 28, 2017 43